Here are the 10-Q quarterly reports from Parabilis Medicines, Inc. (PBLS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PBLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBLS filings page.
Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company developing Helicon peptide therapeutics, reported its first results as a public company for the period ended June 30, 2026. In June, it completed an IPO of 38,525,000 common shares at $20.00 per share and a concurrent private placement of 4,166,666 shares to Regeneron at $18.00 per share, generating aggregate net proceeds of $787.9 million. In addition, Parabilis received a non-refundable $50.0 million upfront payment under its license and collaboration agreement with Regeneron.
These transactions lifted cash and cash equivalents to $1,087.1 million, marketable securities to $33.6 million, and total assets to $1,175.3 million as of June 30, 2026. For the six months ended June 30, 2026, Parabilis recorded collaboration revenue of $148 thousand, research and development expense of $77.1 million, general and administrative expense of $21.4 million, and a net loss of $97.8 million compared to $73.1 million in the prior-year period. The accumulated deficit was $639.3 million, but management states that existing cash, cash equivalents and marketable securities are expected to fund operations for at least twelve months from issuance.